Jane W. Newburger
Congenital Heart Disease, Vol.12, No.5, pp. 641-643, 2017, DOI:10.1111/chd.12502
Abstract Medical therapies in patients with Kawasaki disease (KD) are administered to reduce the prevalence of coronary aneurysms, reduce systemic inflammation, and prevent coronary thrombosis. All
patients with acute KD should be treated with intravenous immunoglobulin (IVIG) 2 g/kg, generally
administered over 10–12 hours. Aspirin has never been shown to prevent aneurysms, but is given
for its anti-inflammatory and antipyretic effects until the patient has been afebrile for 2 days,
then lowered to an antiplatelet dose. Adjunctive therapy with a longer course of corticosteroids,
together with IVIG and aspirin, may be considered for primary treatment in patients at high risk
for… More >
Login
Register
